This wasn't funded by MVP.
In fact, (interestingly) I believe most of the studies I post here aren't.
Funding Internal funding was used to conduct this study. SPC receives funding from the US Department of Defense (MIRROR, HU0001-15-2-0003; Congressionally Directed Medical Research Program, 105637007) and National Institutes of Health (GR101558, R01DA048206-01, U24NS115708, 1UH3135804).
Competing interests SPC is a consultant for Avanos, SPR Therapeutics, Persica, and SWORD, and has previously served as a consultant for Clearing and Scilex in the past 3 years. Currently, SPC is the editorial board member of RAPM. SS, PK, WI, NT, SL, RS, and KP have no conflicts of interest to declare.
Another Positive Study, page-167
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.005(1.14%) |
Mkt cap ! $50.13M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 44.5¢ | 42.0¢ | $74.04K | 171.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40558 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 1342 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MVP (ASX) Chart |